Fluticasone furoate/umeclidinium bromide/vilanterol
Fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI), sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The medications work in different ways: fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta-agonist (LABA).
Q1779868
fixed-dose combination
Concept
Q199804
chronic obstructive pulmonary disease
Concept
Q2166700
fluticasone furoate
Concept
Q210420
corticosteroid
Concept
Q15624035
umeclidinium
Concept
Q3001265
muscarinic antagonist
Concept
Q15053666
vilanterol
Concept
Q6671832
long-acting beta-agonist
UNK
Q85761419
Fluticasone furoate/umeclidinium bromide/vilanterol
Concept
instance of